BioSpace News Archive

Konica Minolta Healthcare Americas, Inc. announced the introduction of the company’s acclaimed KDR® Primary U-arm Digital Radiography and mKDR Xpress™ Mobile X-ray systems in select Latin America countries.* Chosen by numerous healthcare facilities throughout North America, the KDR Primary and mKDR Xpress will complement Konica Minolta’s existing portfolio of CR systems, DR retrofit solutions and PACS throughout the region.

Ahead of its planned spinoff from GE the first week of January 2023, GE Healthcare reveals over 40 solutions that aim to improve patient outcomes and increase healthcare efficiency at the Radiological Society of North America’s 2022 Annual Meeting.

Seno Medical, makers of the Imagio® Breast Imaging System - a revolutionary new modality in breast imaging - will officially launch the commercially available system at the annual RSNA Scientific Assembly and Annual Meeting starting November 27 through December 1 in Chicago.

Lyvgen Biopharma announced an open label, phase 2, multicenter, randomized trial of LVGN7409 plus docetaxel or, in collaboration with Bristol Myers Squibb, nivolumab in patients with advanced/metastatic Non-Small Cell Lung Cancer.

Volpara Health Technologies Ltd., a global leader in software for the early detection of cancer, will showcase advancements in personalized breast care at the Annual Radiological Society of North America meeting, November 27 to December 1, 2022.

GE Healthcare announced the launch of SIGNA Experience, a platform of four synergistic technologies that help users through the diagnostic journey.

Innovent Biologics, Inc. announced that clinical data from multiple trials in relation to TYVYT®, olverembatinib, IBI188, IBI110 and IBI939 will be presented at the upcoming international medical conferences.

Royal Philips, a global leader in health technology, announced its portfolio of smart diagnostic systems and transformative workflow solutions featured at the Radiological Society of North America annual meeting.

Edwards Lifesciences Corporation announced that one-year results on patients treated in the single-arm, prospective, global, multi-center TRISCEND study of the company’s EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes.

Diamyd Medical announced that the U.S. Food and Drug Administration has lifted the partial clinical hold on the confirmatory Phase III trial DIAGNODE-3, evaluating the safety and efficacy of the precision medicine and antigen-specific immunotherapy Diamyd® in individuals recently diagnosed with type 1 diabetes.